2025 annual financial data
Inhibikase Therapeutics 2025 Net margin
Direct answer
Net margin was Not calculable.
Operating income was -51.97M USD and net income was -48.26M USD.
Operating cash flow was -27.79M USD.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -51.97M USD
- Net income
- -48.26M USD
- Operating cash flow
- -27.79M USD
Explore related company data
View all 2025 financial metricsView RevenueView Operating incomeView Net incomeView Operating cash flowView Revenue growthView Operating income growthView Net income growthView Operating cash flow growthView Operating marginView Operating cash flow marginView all Inhibikase Therapeutics financial years